Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HMGCR | P04035 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625500 | 0.91 | KMO (0.39) | KMOTLR8 | |
| SCHEMBL31000813 | 0.80 | KMO (0.63) | KMOTLR8L3MBTL1CSF1RKMT2A | |
| SCHEMBL25888734 | 0.73 | L3MBTL1 (0.39) | KMOTLR8L3MBTL1HMGCRKMT2A | |
| SCHEMBL29170167 | 0.72 | CA2 (0.48) | KMOTLR8L3MBTL1KMT2AMEN1 | |
| SCHEMBL29914143 | 0.72 | CA2 (0.48) | KMOTLR8L3MBTL1KMT2AMEN1 | |
| SCHEMBL24692153 | 0.72 | KMO (0.54) | KMOL3MBTL1CSF1RABL1HRH4 | |
| SCHEMBL2076056 | 0.72 | KMO (0.54) | KMOL3MBTL1CSF1RABL1HRH4 | |
| SCHEMBL278866 | 0.71 | CA2 (0.37) | NPC1RAB9A | |
| SCHEMBL22601521 | 0.70 | CYP11B2 (0.40) | KMOL3MBTL1KMT2ANPC1RAB9A | |
| SCHEMBL28964988 | 0.70 | KMO (0.36) | KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | KMO 1131/4885TLR8 4705/4885L3MBTL1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.